Details of Disease

General Information of Disease (ID: DISWE1R7)

Disease Name Acute biphenotypic leukaemia
Synonyms B- and T-cell mixed leukemia; B- and T-cell mixed leukaemia
Disease Class 2B33: Malignant haematopoietic neoplasm
Definition An acute leukemia of ambiguous lineage characterized by blasts which coexpress myeloid and T or B lineage antigens or concurrent B and T lineage antigens. (WHO, 2001)
Disease Hierarchy
DISQQE3G: Primary bone lymphoma
DISNCHV9: Mixed phenotype acute leukemia
DIS87TGM: Acute lymphoblastic leukaemia
DISWE1R7: Acute biphenotypic leukaemia
ICD Code
ICD-11
ICD-11: 2B33.4
Disease Identifiers
MONDO ID
MONDO_0020322
MESH ID
D015456
UMLS CUI
C0023464
MedGen ID
7318
HPO ID
HP:0005531
SNOMED CT ID
128818009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Flotetuzumab DMVR6OM Phase 2 NA [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 2 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
FLT3 TTGJCWZ moderate Biomarker [2]
KAT6A TT6O1J0 Strong Genetic Variation [3]
------------------------------------------------------------------------------------
This Disease Is Related to 3 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
BAALC OTUZSRVF Strong Altered Expression [4]
CT45A2 OT9X9KTC Strong Biomarker [5]
NCOA2 OTMQFPBB Strong Genetic Variation [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03739606) Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer. U.S. National Institutes of Health.
2 Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations.Haematologica. 2014 May;99(5):848-57. doi: 10.3324/haematol.2013.095604. Epub 2014 Jan 17.
3 MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.Mol Cancer. 2007 Aug 13;6:51. doi: 10.1186/1476-4598-6-51.
4 Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization.Ann Hematol. 2013 Jun;92(6):747-58. doi: 10.1007/s00277-013-1694-4. Epub 2013 Feb 15.
5 A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia.BMC Cancer. 2010 Sep 29;10:518. doi: 10.1186/1471-2407-10-518.